Achilles Therapeutics plc
ACHLNASDAQHealthcare
$1.48
+$0.01(+0.68%)
Market Cap$60828000
P/E Ratio—
52W High$1.51
52W Low$0.63
Achilles Therapeutics plc (ACHL) Earnings: Dates, EPS & Revenue History
Quarterly EPS vs. estimates, revenue surprises, next earnings date, and analyst consensus.
ACHL · earnings · updated Jun 9, 2026
Latest Earnings
Q2 FY2025Report Date: Apr 3, 2025EPS Actual
-$0.46
Est. -$0.36 · -27.8%
Revenue
—
Fiscal Period
Q2 FY2025
FY ends December
Report Date
Apr 3, 2025
After Market Close
▼ Miss EPS
ACHL reports quarterly as a NASDAQ-listed Biotechnology company. Fiscal year ends in December. Data: FMP · Updated hourly.
Next Earnings Date
Days Away
84
days
Expected Date
Sep 1, 2026
Fiscal Period
Q3 FY2026
Release Time
◌ Time TBD (Unconfirmed)EPS Est.
—
Days Away84
Expected DateSep 1, 2026
Fiscal PeriodQ3 FY2026
Release TimeTime TBD (Unconfirmed)
EPS Est.—
EPS & Revenue vs. Estimates
Actual (Beat)
Actual (Miss)
Estimated
Earnings History
| Period | Report Date | EPS Est. | EPS Actual | EPS Surpr. | Revenue | Rev. Est. | Rev. Surpr. |
|---|---|---|---|---|---|---|---|
| ◌ Q4 FY2025 | Nov 12, 2025 | — | — | — | — | — | — |
| ◌ Q3 FY2025 | Aug 12, 2025 | — | — | — | — | — | — |
| ◌ Q2 FY2025 | May 6, 2025 | — | — | — | — | — | — |
| ▼ Q2 FY2025 | Apr 3, 2025 | -$0.36 | -$0.46 | -27.8% | — | — | — |
| ▼ Q4 FY2024 | Nov 14, 2024 | -$0.41 | -$0.48 | -17.1% | — | — | — |
| — Q3 FY2024 | Aug 14, 2024 | -$0.41 | -$0.41 | +0.0% | — | — | — |
| — Q2 FY2024 | Apr 4, 2024 | -$0.46 | -$0.46 | +0.0% | — | — | — |
| ▼ Q1 FY2024 | Mar 26, 2024 | -$0.14 | -$0.46 | -228.6% | — | — | — |
Q4 FY2025
Nov 12, 2025
EPS Actual
—
EPS Est.
—
EPS Surpr.
—
Revenue
—
Q3 FY2025
Aug 12, 2025
EPS Actual
—
EPS Est.
—
EPS Surpr.
—
Revenue
—
Q2 FY2025
May 6, 2025
EPS Actual
—
EPS Est.
—
EPS Surpr.
—
Revenue
—
Q2 FY2025
Apr 3, 2025Miss
EPS Actual
-$0.46
EPS Est.
-$0.36
EPS Surpr.
-27.8%
Revenue
—
Q4 FY2024
Nov 14, 2024Miss
EPS Actual
-$0.48
EPS Est.
-$0.41
EPS Surpr.
-17.1%
Revenue
—
Q3 FY2024
Aug 14, 2024
EPS Actual
-$0.41
EPS Est.
-$0.41
EPS Surpr.
+0.0%
Revenue
—
Q2 FY2024
Apr 4, 2024
EPS Actual
-$0.46
EPS Est.
-$0.46
EPS Surpr.
+0.0%
Revenue
—
Q1 FY2024
Mar 26, 2024Miss
EPS Actual
-$0.46
EPS Est.
-$0.14
EPS Surpr.
-228.6%
Revenue
—
Analyst Estimates
Limited analyst coverage (fewer than 3 analysts). Estimates may not reflect market consensus.
EPS Estimates
| Period | Low | Consensus | High | # Analysts |
|---|---|---|---|---|
| Q4 FY2025 | $-0.16 | $-0.16 | $-0.16 | 1 |
| Q3 FY2025 | $-0.17 | $-0.17 | $-0.17 | 1 |
| Q2 FY2025 | $-0.24 | $-0.24 | $-0.24 | 1 |
| Q1 FY2025 | $-0.31 | $-0.31 | $-0.31 | 1 |
| Q4 FY2024 | $-0.36 | $-0.36 | $-0.36 | 1 |
| Q3 FY2024 | $-0.41 | $-0.41 | $-0.41 | 1 |
Revenue Estimates
| Period | Low | Consensus | High | # Analysts |
|---|---|---|---|---|
| Q4 FY2025 | $0.0B | $0.0B | $0.0B | 0 |
| Q3 FY2025 | $0.0B | $0.0B | $0.0B | 0 |
| Q2 FY2025 | $0.0B | $0.0B | $0.0B | 0 |
| Q1 FY2025 | $0.0B | $0.0B | $0.0B | 0 |
| Q4 FY2024 | $0.0B | $0.0B | $0.0B | 0 |
| Q3 FY2024 | $0.0B | $0.0B | $0.0B | 0 |
Earnings Price Reaction
Closing price one trading day before vs. one trading day after each earnings release.
| Period | Report Date | EPS Beat/Miss | Price Before | Price After | 1D Reaction |
|---|---|---|---|---|---|
| ▼ Q2 FY2025 | Apr 3, 2025 | -27.8% | $1.48 | — | — |
| ▼ Q4 FY2024 | Nov 14, 2024 | -17.1% | $1.02 | $1.07 | +4.90% |
| ▲ Q3 FY2024 | Aug 14, 2024 | +0.0% | $0.77 | $0.76 | -1.64% |
| ▲ Q2 FY2024 | Apr 4, 2024 | +0.0% | $1.20 | $0.90 | -24.76% |
| ▼ Q1 FY2024 | Mar 26, 2024 | -228.6% | $1.23 | $1.24 | +0.81% |
| ▼ Q4 FY2023 | Nov 13, 2023 | -10.5% | $0.80 | $0.80 | +0.00% |
| ▼ Q3 FY2023 | Aug 4, 2023 | -5.0% | $1.00 | $1.00 | +0.00% |
| ▼ Q2 FY2023 | May 10, 2023 | -7.3% | $1.00 | $0.95 | -4.89% |
Q2 FY2025—
Report Date
Apr 3, 2025
EPS Beat/Miss
-27.8%
Price Before
$1.48
Price After
—
Q4 FY2024+4.90%
Report Date
Nov 14, 2024
EPS Beat/Miss
-17.1%
Price Before
$1.02
Price After
$1.07
Q3 FY2024-1.64%
Report Date
Aug 14, 2024
EPS Beat/Miss
+0.0%
Price Before
$0.77
Price After
$0.76
Q2 FY2024-24.76%
Report Date
Apr 4, 2024
EPS Beat/Miss
+0.0%
Price Before
$1.20
Price After
$0.90
Q1 FY2024+0.81%
Report Date
Mar 26, 2024
EPS Beat/Miss
-228.6%
Price Before
$1.23
Price After
$1.24
Q4 FY2023+0.00%
Report Date
Nov 13, 2023
EPS Beat/Miss
-10.5%
Price Before
$0.80
Price After
$0.80
Q3 FY2023+0.00%
Report Date
Aug 4, 2023
EPS Beat/Miss
-5.0%
Price Before
$1.00
Price After
$1.00
Q2 FY2023-4.89%
Report Date
May 10, 2023
EPS Beat/Miss
-7.3%
Price Before
$1.00
Price After
$0.95
Avg Beat Reaction-13.20%
Avg Miss Reaction+0.16%
Beat Rate2 / 8 quarters
Largest Move-24.76% (Q2 FY2024)
Data: FMP /historical-price-eod/full · field: close
About Earnings & Data Methodology
Data source: Financial Modeling Prep (FMP) | Updated: Hourly | Surprise%: (Actual − Estimate) / |Estimate| × 100 | Fiscal year: ACHL ends December
Achilles Therapeutics plc (ACHL) most recently reported earnings on April 3, 2025 for Q2 FY2025, posting EPS of $-0.46 — missing the analyst consensus of $-0.36 by -27.8%. The next ACHL earnings date is expected around September 1, 2026.
Each quarter, investors track ACHL earnings for signals on forward guidance and business momentum. For longer-term revenue trends, see the Revenue tab. ACHL revenue tab →
Earnings Glossary
EPS (Earnings Per Share)
Net income ÷ diluted shares outstanding. The primary metric analysts use to gauge quarterly profitability.
Earnings Surprise %
(Actual − Estimate) / |Estimate| × 100. Positive = Beat. Negative = Miss.
Beat / Miss / In-Line
Beat = Actual ≥ Estimate. Miss = Actual < Estimate. In-Line = within ±1%.
BMO / AMC
Before Market Open / After Market Close. Two windows when companies typically release results.
Fiscal Quarter
ACHL's fiscal year ends in December. Fiscal quarters may not align with calendar quarters.
Analyst Consensus
Average EPS/Revenue forecast across all covering analysts. More analysts = more reliable estimate.
Figures tie to FMP earnings calendar, estimates, and SEC 10-Q/10-K filings where noted.
Frequently asked questions
ACHL earnings · 5 questionsAchilles Therapeutics plc's next earnings report is expected around September 1, 2026. ACHL typically reports quarterly — approximately every three months. The exact date is confirmed by the company 2–4 weeks before the release. Time is currently TBD; ACHL historically reports after market close (AMC).
ACHL earnings datewhen is ACHL earningsACHL next earnings datewhen does ACHL report earningsACHL earnings calendar
▸ Source: FMP · Achilles Therapeutics plc SEC filings · US GAAP · Achilles Therapeutics plc SEC 10-K & 10-Q filings · US GAAP · Updated: Jun 9, 2026